Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation

Yeming Han; Shanshan Zhao; Yaoqin Gong; Guihua Hou; Xi Li; Li Li

doi:10.18632/oncotarget.6443

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation

Yeming Han, Shanshan Zhao, Yaoqin Gong, Guihua Hou, Xi Li and Li Li _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:1854-1862. https://doi.org/10.18632/oncotarget.6443

Metrics: PDF 2267 views | HTML 2079 views | ?

Abstract

Yeming Han1, Shanshan Zhao2, Yaoqin Gong2,3, Guihua Hou2, Xi Li2,3,*, Li Li1,*

1Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Department of of Cardiology, Qilu Hospital, Shandong University, Jinan, Shandong, 250012, China

2Laboratory of Experimental Teratology, Ministry of Education, School of Medicine, Shandong University, Jinan, Shandong, 250012, China

3Department of Genetics, School of Medicine, Shandong University, Jinan, Shandong, 250012, China

*These authors contributed equally to this work

Correspondence to:

Li Li, e-mail: [email protected]

Keywords: atherosclerosis, inflammation, serum, proteomics, CDK9

Received: July 29, 2015 Accepted: November 16, 2015 Published: December 01, 2015

ABSTRACT

Atherosclerotic coronary artery disease (CAD) is one of the most prevalent diseases worldwide. Atherosclerosis was considered to be the single most important contributor to CAD. In this study, a distinct serum protein expression pattern in CAD patients was demonstrated by proteomic analysis with two-dimensional gel electrophoresis coupled with mass spectrometry. In particular, CDK9 was found to be highly elevated in serum, monocytes and artery plaque samples of CAD patients. Furthermore, there was high infiltration of CD14+ monocytes/macrophages within artery plaques correlated with the expression of CDK9. Moreover, Flavopiridol (CDK9 inhibitor) could inhibit THP-1 cell (monocytic acute leukemia cell line) proliferation by targeting CDK9. Altogether, These findings indicate that CDK9 represent an important role for inflammation in the pathogenesis of atherosclerosis. It may be a potential biomarker of atherosclerotic inflammation and offer insights into the pathophysiology and targeted therapy for atherosclerotic CAD.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6443

Publication Alerts

Research Papers:

Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation

Abstract